164 related articles for article (PubMed ID: 16099406)
1. Targeted lipidomics and drug abuse research.
Rapaka RS
Prostaglandins Other Lipid Mediat; 2005 Sep; 77(1-4):219-22. PubMed ID: 16099406
[TBL] [Abstract][Full Text] [Related]
2. Targeted lipidomics: signaling lipids and drugs of abuse.
Rapaka RS; Piomelli D; Spiegel S; Bazan N; Dennis EA
Prostaglandins Other Lipid Mediat; 2005 Sep; 77(1-4):223-34. PubMed ID: 16099407
[No Abstract] [Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. The dawn of lipidomics.
Rapaka RS; Hla T; Dey SK
Prostaglandins Other Lipid Mediat; 2005 Sep; 77(1-4):1-3. PubMed ID: 16099385
[No Abstract] [Full Text] [Related]
5. Mass spectrometry: from proteomics to metabolomics and lipidomics.
Griffiths WJ; Wang Y
Chem Soc Rev; 2009 Jul; 38(7):1882-96. PubMed ID: 19551169
[TBL] [Abstract][Full Text] [Related]
6. Lipidomics, drugs of abuse and NIDA.
Rapaka RS
Life Sci; 2005 Aug; 77(14):1519-21. PubMed ID: 15961116
[No Abstract] [Full Text] [Related]
7. Analytical strategies in lipidomics and applications in disease biomarker discovery.
Hu C; van der Heijden R; Wang M; van der Greef J; Hankemeier T; Xu G
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Sep; 877(26):2836-46. PubMed ID: 19233743
[TBL] [Abstract][Full Text] [Related]
8. The lipid maps initiative in lipidomics.
Schmelzer K; Fahy E; Subramaniam S; Dennis EA
Methods Enzymol; 2007; 432():171-83. PubMed ID: 17954217
[TBL] [Abstract][Full Text] [Related]
9. The emerging field of lipidomics.
Wenk MR
Nat Rev Drug Discov; 2005 Jul; 4(7):594-610. PubMed ID: 16052242
[TBL] [Abstract][Full Text] [Related]
10. Involving the pharmaceutical and biotech communities in medication development for substance abuse.
Gorodetzky CW; Grudzinskas C
Pharmacol Ther; 2005 Oct; 108(1):109-18. PubMed ID: 16038981
[TBL] [Abstract][Full Text] [Related]
11. An update on lipidomics: progress and application in biomarker and drug development.
Han X
Curr Opin Mol Ther; 2007 Dec; 9(6):586-91. PubMed ID: 18041669
[TBL] [Abstract][Full Text] [Related]
12. Future of toxicology--lipidomics, an important emerging area for toxicologists: focus on lipid oxidation products.
Berliner JA; Zimman A
Chem Res Toxicol; 2007 Jun; 20(6):849-53. PubMed ID: 17489606
[No Abstract] [Full Text] [Related]
13. How to study lipidomes.
Seppänen-Laakso T; Oresic M
J Mol Endocrinol; 2009 Mar; 42(3):185-90. PubMed ID: 19060177
[TBL] [Abstract][Full Text] [Related]
14. Lipids and drugs of abuse.
Hillard CJ
Life Sci; 2005 Aug; 77(14):1531-42. PubMed ID: 15946699
[TBL] [Abstract][Full Text] [Related]
15. Blending addiction research and practice: strategies for technology transfer.
Condon TP; Miner LL; Balmer CW; Pintello D
J Subst Abuse Treat; 2008 Sep; 35(2):156-60. PubMed ID: 18337054
[TBL] [Abstract][Full Text] [Related]
16. [Research progress and application of shotgun lipidomics].
Bai XJ; Ding W
Sheng Li Ke Xue Jin Zhan; 2010 Oct; 41(5):323-8. PubMed ID: 21416920
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of plasma lipidomics in cardiovascular drug discovery.
Puri R; Duong M; Uno K; Kataoka Y; Nicholls SJ
Expert Opin Drug Discov; 2012 Jan; 7(1):63-72. PubMed ID: 22468894
[TBL] [Abstract][Full Text] [Related]
18. Lipidomics in drug discovery.
Vihervaara T; Suoniemi M; Laaksonen R
Drug Discov Today; 2014 Feb; 19(2):164-70. PubMed ID: 24055840
[TBL] [Abstract][Full Text] [Related]
19. Focused metabolomic profiling in the drug development process: advances from lipid profiling.
Morris M; Watkins SM
Curr Opin Chem Biol; 2005 Aug; 9(4):407-12. PubMed ID: 15979378
[TBL] [Abstract][Full Text] [Related]
20. Lipidomics and lipid profiling in metabolomics.
German JB; Gillies LA; Smilowitz JT; Zivkovic AM; Watkins SM
Curr Opin Lipidol; 2007 Feb; 18(1):66-71. PubMed ID: 17218835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
